BiologicalDrug

PD-L1 clinical trials

studies test it: 4
open now: 1
in phase 3: 1
first study started: 2018

Keep track of what changes. Save the PD-L1 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

How studies write it

Studies that test it under each name

Studies by the year they started

4 studies that test it; most in 2018 (2)

Studies that test PD-L1, by start year
Year	Studies
2018	2
2019	1
2023	1

By phase

A phase 1/2 study counts in both.

Phase 1: 2
Phase 2: 3
Phase 3: 1

What it is tested for

Each study’s main condition, where its own words name it.

Urinary Bladder Neoplasms: 1
Melanoma: 1
Carcinoma, Basal Cell: 1
Head and Neck Neoplasms: 1

Who runs them

Industry 0 · Other 4

University of California, Davis (1) · Inge Marie Svane (1) · Herlev and Gentofte Hospital (1) · Second Affiliated Hospital of Guangzhou Medical University (1)

Often tested with

Tested in the same studies.

Indoleamine 2,3-dioxygenase Peptide Vaccine (2) · Pembrolizumab (1) · Nivolumab (1) · Programmed Cell Death 1 Receptor (1) · Programmed cell death 1 ligand 1 (1) · Immune Checkpoint Inhibitors (1)

Studies

Open first, then newest update. How each study uses PD-L1 is read from its arms, and is right about nine times in ten.

Testing it · 4

Given in every arm · 2 — PD-L1 is usual care beside what is tested